Home/Hedge Fund Intelligence/Oruka Therapeutics, Inc.
Nasdaq: ORKAStockForm 13F30 Jun 2026

Hedge funds that hold Oruka Therapeutics, Inc. Nasdaq: ORKA

CUSIP 687604108 · who reports it, how much, and how much it matters to them

33 of the 720 hedge fund managers we track reported shares of Oruka Therapeutics, Inc. (Nasdaq: ORKA) on Form 13F for 30 June 2026. Between them they reported USD 1.8bn. The largest position belongs to Fairmount Funds Management, at USD 353m.

Managers reporting it33of 720 we track
Value they reportUSD 1.8bnshares only, 30 Jun 2026
Funds they run256with a file on PPLI.com
Largest positionUSD 353mFairmount Funds Management
Typical weight0.4%median share of a manager's book
Heaviest weight23.3%Fairmount Funds Management

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

33 managers, USD 1.8bn between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Oruka Therapeutics, Inc., largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Fairmount Funds Management2 funds on PPLI.comUSD 353m23.3%
2RTW Investments2 funds on PPLI.comUSD 299m2.6%
3Deep Track Capital1 fund on PPLI.comUSD 183m2.7%
4Ra Capital Management1 fund on PPLI.comUSD 148m1.3%
5Viking Global Investors4 funds on PPLI.comUSD 143m0.4%
6Perceptive Advisors6 funds on PPLI.comUSD 128m1.9%
7Polar Capital LLP26 funds on PPLI.comUSD 117m0.3%
8Citadel Advisors32 funds on PPLI.comUSD 106m0.0%
9Summit Partners Public Asset Management14 funds on PPLI.comUSD 63m1.1%
10Cormorant Asset Management1 fund on PPLI.comUSD 51m2.6%
11Adage Capital Management1 fund on PPLI.comUSD 34m0.0%
12Holocene Advisors2 funds on PPLI.comUSD 29m0.1%
13Braidwell12 funds on PPLI.comUSD 26m1.0%
14Great Point Partners2 funds on PPLI.comUSD 17m3.3%
15Sio Capital Management4 funds on PPLI.comUSD 17m2.8%
16PFM Health Sciences3 funds on PPLI.comUSD 15m1.3%
17Exoduspoint Capital Management7 funds on PPLI.comUSD 14m0.1%
18Apis Capital Advisors4 funds on PPLI.comUSD 11m1.0%
19Atika Capital Management3 funds on PPLI.comUSD 9.5m0.6%
20Burkehill Global Management5 funds on PPLI.comUSD 4.8m0.2%
21HighVista Strategies27 funds on PPLI.comUSD 4m0.9%
22Schonfeld Strategic Advisors30 funds on PPLI.comUSD 3.3m0.0%
23Palo Alto Investors6 funds on PPLI.comUSD 3.2m0.4%
24Artia Global Partners1 fund on PPLI.comUSD 3.2m0.6%
25Millennium Management6 funds on PPLI.comUSD 3.1m0.0%
26Freestone Grove Partners1 fund on PPLI.comUSD 2.1m0.0%
27Atom Investors1 fund on PPLI.comUSD 1.5m0.1%
28J. Goldman & Co.1 fund on PPLI.comUSD 1.2m0.0%
29Rock Springs Capital Management2 funds on PPLI.comUSD 1.1m0.1%
30Balyasny Asset Management25 funds on PPLI.comUSD 1.1m0.0%
31Persistent Asset Partners10 funds on PPLI.comUSD 674,0000.2%
32Engineers Gate Manager1 fund on PPLI.comUSD 350,0000.0%
33Voleon Capital Management13 funds on PPLI.comUSD 339,0000.0%
Next: where it matters most
Where it matters most

For Fairmount Funds Management it is 23.3% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Fairmount Funds ManagementUSD 353m23.3%
2Great Point PartnersUSD 17m3.3%
3Sio Capital ManagementUSD 17m2.8%
4Deep Track CapitalUSD 183m2.7%
5Cormorant Asset ManagementUSD 51m2.6%
6RTW InvestmentsUSD 299m2.6%
7Perceptive AdvisorsUSD 128m1.9%
8PFM Health SciencesUSD 15m1.3%
9Ra Capital ManagementUSD 148m1.3%
10Summit Partners Public Asset ManagementUSD 63m1.1%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Oruka Therapeutics, Inc.

What is the ticker symbol of Oruka Therapeutics, Inc.?

Oruka Therapeutics, Inc. trades under the symbol ORKA on the Nasdaq. Its CUSIP, the code used on Form 13F, is 687604108.

Which hedge funds own Oruka Therapeutics, Inc. (Nasdaq: ORKA)?

33 of the 720 hedge fund managers PPLI.com tracks reported Oruka Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Fairmount Funds Management (USD 353m), RTW Investments (USD 299m), Deep Track Capital (USD 183m), Ra Capital Management (USD 148m) and Viking Global Investors (USD 143m).

How many hedge funds hold Oruka Therapeutics, Inc.?

33 managers in our coverage reported it, and between them they run 256 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Oruka Therapeutics, Inc.?

Fairmount Funds Management, where the position was 23.3% of the reported 13F book at 30 June 2026.

Does this show who is short Oruka Therapeutics, Inc.?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Oruka Therapeutics, Inc. or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.